Louis Moore Bacon's RLAY Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 414,005 shares of Relay Therapeutics, Inc. (RLAY) worth $7.75 M, representing 0.11% of the portfolio. First purchased in 2020-Q4, this short-term holding has been held for 3 quarters.
Based on 13F filings, Louis Moore Bacon has maintained this position in RLAY for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 414,005 shares. Largest reduction occurred in Q1 2021, reducing 130,162 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Relay Therapeutics (RLAY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Relay Therapeutics (RLAY) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +414,005 | New Buy | 414,005 | $18.71 |
| Q1 2021 | -130,162 | Sold Out | 0 | $0.00 |
| Q4 2020 | +130,162 | New Buy | 130,162 | $41.56 |
Louis Moore Bacon's Relay Therapeutics Investment FAQs
Louis Moore Bacon first purchased Relay Therapeutics, Inc. (RLAY) in Q4 2020, acquiring 130,162 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Relay Therapeutics, Inc. (RLAY) for 3 quarters since Q4 2020.
Louis Moore Bacon's largest addition to Relay Therapeutics, Inc. (RLAY) was in Q2 2026, adding 414,005 shares worth $7.75 M.
According to the latest 13F filing for Q2 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 414,005 shares of Relay Therapeutics, Inc. (RLAY), valued at approximately $7.75 M.
As of the Q2 2026 filing, Relay Therapeutics, Inc. (RLAY) represents approximately 0.11% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Relay Therapeutics, Inc. (RLAY) was 414,005 shares, as reported at the end of Q2 2026.